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mesylate was used as an internal standard for Rasagiline. Zorbax Eclipse Plus C18 (2.1 mm 50
mm, 3.5 mm) column provided chromatographic separation of analyte followed by detection with
mass spectrometry. The method involved simple isocratic chromatographic condition and mass
spectrometric detection in the positive ionization mode using an API-4000 system. The total run
time was 3.0 min. The proposed method has been validated with the linear range of 5–12000 pg/mL
for Rasagiline. The intra-run and inter-run precision values were within 1.3%–2.9% and 1.6%–
2.2% respectively for Rasagiline. The overall recovery for Rasagiline and Rasagiline-13C3 mesylate
analog was 96.9% and 96.7% respectively. This validated method was successfully applied to the
bioequivalence and pharmacokinetic study of human volunteers under fasting condition.
& 2012 Xian Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.rsity. Production and hosting
n Jiaotong University.
.001
8259567.
oo.com (B.R. Challa).
1. Introduction
Rasagiline ((1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine) is
used as a monotherapy in early Parkinson’s disease or as an
adjunct therapy in more advanced cases [1–3]. The empirical
formula is C12H13N with its molecular weight 171.24 (Fig. 1).
Rasagiline is rapidly absorbed, reaching peak plasma concentra-
tion (Cmax) in approximately 1 h. The absolute bioavailability of
Rasagiline is about 36%. Food does not affect the tmax of
Rasagiline, although Cmax and exposure (AUC) decreased by
Figure 1 Chemical structures of Rasagiline (A) and Rasagili-
ne-13C3 mesylate (B).
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with a high fat meal. Rasagiline’s pharmacokinetics is linear with
doses over the range of 1–10 mg. Its mean steady-state half-life is
3 h but there is no correlation of pharmacokinetics with its
pharmacological effect. Plasma protein binding ranges from
88%–94% with a mean extent of binding of 61%–63% to human
albumin over the concentration range of 1–100 ng/mL. Rasagiline
is almost metabolized in the liver and undergoes urinary excretion.
Half-life of Rasagiline is about 38–45 min [4].
Literature survey reveals that only a few methods were
reported for quantiﬁcation of Rasagiline in human plasma and
pharmaceutical analysis [5–9]. These include HPLC [5,6],
crystallographic analysis [7], and LC-MS/MS [8,9]. Only two
methods were reported for quantiﬁcation of Rasagiline in
human plasma with LC-MS/MS [8,9].
Song et al. [8] developed a method in a concentration range
0.01–40 ng/mL in human plasma and 0.025–40 ng/mL in urine
with runtime 5.5 min. Papavarin was used as an internal
standard and the pharmacokinetic study was conducted in
30 human volunteers. The main drawbacks of this method are
longer runtime and unsuitable internal standard.
The drawbacks of Song et al. are overcome by Ma et al. [9]
with shorter runtime of 3.5 min for each sample in a
concentration range of 0.02–50 ng/mL, Pseudoephedrine was
used as an internal standard and the pharmacokinetic study
was conducted in 12 human volunteers. The main drawbacks
of Ma et al. [9] method are sensitivity which is not achieved
when compared with Song et al. [8] and suitable internal
standard like deuterated or analogs of Rasagiline is not used.
The purpose of the present investigation is to explore rapid run
analysis time (3 min), more sensitive method (5 pg/mL), with the
small amount of plasma sample (100 mL plasma) utilization during
sample processing, simple extraction and analyte comparison with
isotope labeled internal standard (Rasagiline-13C3 mesylate).2. Experimental
Rasagiline and Rasagiline-13C3 mesylate were obtained from TLC
PharmaChem, Canada. LC grade methanol, methyl t-butyl ether
and dichloromethane were purchased from J.T. Baker Inc.
(Phillipsburg, NJ, USA). Analytical reagent grade formic acid
and Na2CO3 were procured from Merck (Mumbai, India).
Human plasma (K2EDTA) was obtained from Doctors Patholo-
gical Lab, Hyderabad. The AZILECTs tablets, containing 1 mg
Rasagiline per tablet, were obtained from Teva Pharma (USA).
2.1. Instrumentation
An HPLC system (1200 series model, Agilent Technologies,
Waldbronn, Germany) connected with mass spectrometer API4000 triple quadrupole instrument (ABI-SCIEX, Toronto,
Canada) was used. Data processing was performed with
Analyst 1.4.1 software package (SCIEX).
2.2. Detection
The mass spectrometer was operated in the multiple reaction
monitoring (MRM) modes. Sample introduction and ionization
were electrospray ionization in the positive ion mode. Sources
dependent parameters optimized were as follows: nebulizer gas
ﬂow, 30 psi; curtain gas ﬂow, 25 psi; ion spray voltage, 2000 V;
temperature (TEM), 375 1C. The compound dependent para-
meters such as the declustering potential (DP), focusing potential
(FP), entrance potential (EP), collision energy (CE), cell exit
potential (CXP) were optimized during tuning as 40, 35, 10, 12,
8 eV for Rasagiline and Rasagiline-13C3 mesylate, respectively.
The collision activated dissociation (CAD) gas was set at 4 psi
using nitrogen gas. Quadrupole 1 and quadrupole 3 were both
maintained at a unit resolution and dwell time was set at 300 ms
for Rasagiline and Rasagiline-13C3 mesylate. The mass transitions
were selected as m/z 172.1-117.1 for Rasagiline and m/z 175.1-
117.1 for Rasagiline-13C3 mesylate. The data acquisition was
ascertained by Analyst 1.5.1 software.
2.3. Chromatography
Zorbax Eclipse Plus C18 (2.1 mm 50 mm, 3.5 mm) was
selected as the analytical column. Column temperature was
set at 45 1C. Mobile phase composition was 0.1% formic
acid:methanol (80:20, v/v). Source ﬂow rate was 300 mL/min
without split with injection volume of 10 mL. Rasagiline and
Rasagiline-13C3 mesylate were eluted at 1.270.2 min, with a
total run time of 3.0 min for each sample.
2.4. Calibration curve and quality control samples
Two separate stock solutions of Rasagiline were prepared for bulk
spiking of calibration curve and quality control samples for the
method validation exercise as well as the subject sample analysis.
The stock solutions of Rasagiline and Rasagiline-13C3 mesylate
were prepared in methanol at free base concentration of 50 mg/
mL. Primary dilutions and working standard solutions were
prepared from stock solutions using water:methanol (50:50, v/v)
solvent mixture. These working standard solutions were used to
prepare the calibration curve and quality control samples. Blank
human plasma was screened prior to spiking to ensure it was free
of endogenous interference at retention times of Rasagiline and
internal standard Rasagiline-13C3 mesylate. Ten point standard
curve and four quality control samples were prepared by spiking
the blank plasma with an appropriate amount of Rasagiline.
Calibration samples were made at concentrations of 5.0, 10.0,
100.0, 600.0, 1200.0, 2400.0, 4800.0, 7200.0, 9600.0 and
12000.0 pg/mL and quality control samples were made at con-
centrations of 5.0, 15.0, 4500.0 and 9000.0 pg/mL for Rasagiline.
2.5. Sample preparation
For sample preparation, 100 mL of plasma sample or Rasagi-
line spiked standard or quality control plasma sample was
added to 5 mL ria vial tubes. 50 mL of internal standard and
200 mL of 1 M Na2CO3 solution were added and vortexed
R.K. Konda et al.344brieﬂy. Then liquid–liquid extraction with 3 mL of extraction
solvent (Methyl tertiary butyl ether (MTBE):Dichloromethane
(DCM) (3:1, v/v)) was added to each tube and vortexed for
10 min. After centrifugation at 4000 rpm for approximately
10 min at 20 1C, the supernatant was transferred to respective
ria vial tubes and evaporated to dryness under nitrogen at
25 1C. Finally, the residue was redissolved in 200 mL of
reconstitution solution (MeOH:0.1% formic acid(1:4)).
Further, samples were centrifuged at 4000 rpm for approxi-
mately 2 min at 20 1C and the supernatant was transferred to
auto sampler vials with caps and 10 mL of sample was injected
into the LC-MS/MS system.
2.6. Selectivity
Selectivity was performed by analyzing the human blank
plasma samples from six different sources (donors) with an
additional hemolyzed group and lipedimic group to test for
interference at the retention time of analytes.
2.7. Matrix effect
Matrix effect for Rasagiline and internal standard was
evaluated by comparing the peak area ratio in the post-
extracted plasma sample from 6 different drug-free blank
plasma samples and neat reconstitution samples. Experiments
were performed at MQC levels in triplicate with six different
plasma lots with the acceptable precision (% CV) of r15%.
2.8. Precision and accuracy
It was determined by replicate analysis of quality control
samples (n¼6) at a lower limit of quantiﬁcation (LLOQ), low
quality control(LQC), medium quality control (MQC), high
quality control (HQC) levels. The % CV should be less than
15%, and accuracy should be within 15% except LLOQ where
it should be within 20%.
2.9. Recovery
The extraction efﬁciencies of Rasagiline and Rasagiline-13C3
mesylate were determined by analysis of six replicates at each
quality control concentration level for Rasagiline and at one
concentration for Rasagiline-13C3 mesylate. The percentage
recovery was evaluated by comparing the peak areas of
extracted standards to the peak areas of nonextracted stan-
dards (spiked into mobile phase).
2.10. Stability
Stock solution stability was performed by comparing the area
response of analyte and internal standard in the stability
sample, with the area response of sample prepared from fresh
stock solution. Stability studies in plasma were performed at
the LQC and HQC concentration levels using six replicates at
each level. Analyte was considered stable if the change is less
than 15% as per US FDA guidelines [10]. The stability of
spiked human plasma samples stored at room temperature
(bench top stability) was evaluated for 24 h. The stability of
spiked human plasma samples stored at 2–8 1C in autosampler
(autosampler stability) was evaluated for 55 h. Theautosampler sample stability was evaluated by comparing
the extracted plasma samples that were injected immediately
(time 0 h), with the samples that were reinjected after storing
in the autosampler at 2–8 1C for 26 h. The reinjection
reproducibility was evaluated by comparing the extracted
plasma samples that were injected immediately (time 0 h),
with the samples that were re-injected after storing in the
autosampler at 2–8 1C for 26 h. The freeze–thaw stability was
conducted by comparing the stability samples that had been
frozen at 30 1C and thawed three times, with freshly spiked
quality control samples. Six aliquots each of LQC and HQC
concentration levels were used for the freeze–thaw stability
evaluation. For long-term stability evaluation the concentra-
tions obtained after 78 days were compared with initial
concentrations.
2.11. Application of method
The validated method has been successfully used to analyze
Rasagiline concentrations in 22 human volunteers under
fasting conditions after administration of a single tablet
containing 1 mg (1 1 mg) Rasagiline as an oral dose. The
study design was a randomized, two-period, two-sequence,
two-treatment single dose, open label, bioequivalence study
using AZILECTs manufactured by Teve Pharma, USA as the
reference formulation. The test formulation was conducted for
APL Research Pvt. Ltd., India. The study was conducted
according to current GCP guidelines and after obtaining
signed consent of the volunteers. Before conducting the study
it was also approved by an authorized ethics committee. There
were a total of 19 blood collection time points including the
predose sample, per period. The blood samples were collected
at time intervals (0, 0.083, 0.167, 0.25, 0.333, 0.417, 0.5, 0.667,
0.833, 1, 1.25, 1.5, 2, 2.5, 3, 3.75, 4.5, 5.5 and 6.5 h) in separate
vacutainers containing K2EDTA as an anticoagulant. The
plasma from these samples was separated by centrifugation at
4000 rpm within the range of 10 1C. The plasma samples thus
obtained were stored at 30 1C until analysis. The pharma-
cokinetic parameters were computed using Win-Nonlins
software version 5.2 and 90% conﬁdence interval was com-
puted using SASs software version 9.2.3. Results and discussion
3.1. Method development
During method development, different options were evaluated
to optimize mass spectrometry detection parameters, chroma-
tography and sample extraction.
3.1.1. Mass spectrometry detection parameters optimization
Electrospray ionization (ESI) provided a maximum response
over atmospheric pressure chemical ionization (APCI) mode,
and was chosen for this method. The instrument was opti-
mized to obtain sensitivity and signal stability during infusion
of the analyte in the continuous ﬂow of mobile phase to
electrospray ion source operated at both polarities at a ﬂow
rate of 10 mL/min. Rasagiline gave more response in positive
ion mode as compare to the negative ion mode. The pre-
dominant peaks in the primary ESI spectra of Rasagiline
and Rasagiline-13C3 mesylate correspond to the MHþ ions at
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ions of Rasagiline and Rasagiline-13C3 mesylate scanned in
quadrupole 3 after a collision with nitrogen in quadrupole 2
had an m/z of 117.1 and 117.2 respectively (Fig. 2B and D).
3.1.2. Chromatography optimization
Initially, a mobile phase consisting of ammonium acetate and
acetonitrile in varying combinations was tried, but a low
response was observed. The mobile phase containing acetic
acid:acetonitrile (20:80, v/v) and acetic acid:methanol (20:80,
v/v) gave the better response, but poor peak shape was
observed. A mobile phase of 0.1% formic acid in water in
combination with methanol and acetonitrile with varying
combinations was tried. The best signal along with a marked
improvement in the peak shape was observed for Rasagiline
and Rasagiline-13C3 mesylate using a mobile phase containing
0.1% formic acid in water in combination with methanol
(20:80, v/v). Short length columns, such as Symmetry
Shield RP18 (50 mm 2.1 mm, 3.5 mm), Inertsil ODS-2V
(50 mm 4.6 mm, 5 mm), Hypurity C18 (50 mm 4.6 mm,
5 mm) and Hypurity Advance (50 mm 4.0 mm, 5 mm),
YMC basic (50 mm 2 mm, 5 mm), Zorbax Eclipse Plus C18
(2.1 mm 50 mm, 3.5 mm), were tried during the method
development. The best signal and good peak shape was
obtained using the Zorbax Eclipse Plus C18 (2.1 mm 50 mm,Figure 2 Mass spectra (A) Rasagiline Parent ion, (B) Rasagilin
(D) Rasagiline-13C3 mesylate Product ion.3.5 mm) column. It gave satisfactory peak shapes for both
Rasagiline and Rasagiline-13C3 mesylate. Flow rate of 0.3 mL/
min without splitter was used and reduced the run time to
3.0 min. Both the drug and internal standard were eluted in
shorter time at 2.0 min. For an LC-MS/MS analysis, utiliza-
tion of stable isotope-labeled or suitable analog drugs as an
internal standard proves helpful when a signiﬁcant matrix
effect is possible. In our case, Rasagiline-13C3 mesylate was
found to be best for the present purpose. The column oven
temperature was kept at a constant temperature of about
45 1C. Injection volume of 10 mL sample is adjusted for better
ionization and chromatography.
3.1.3. Extraction optimization
Prior to load the sample for LC injection, the co-extracted
proteins should be removed from the prepared solution. For
this purpose, initially we tested with different extraction
procedures like Protein precipitation(PPT), Liquid–liquid extra-
ction(LLE) and Solid phase extraction(SPE). We found ion
suppression effect in protein precipitation method for the drug
and internal standard. Further, we tried with SPE and LLE.
Out of all, we observed LLE is suitable for extraction of the
drug and internal standard. We tried with several organic
solvents (ethyl acetate, chloroform, n-hexane, dichloromethane
and methyl tertiary butyl ether) individually as well withe Product ion, (C) Rasagiline-13C3 mesylate Parent ion, and
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sample. In our case methyl tertiary butyl ether:dichloromethane
(75:25) combination served as good extraction solvent. Auto
sampler wash is optimized as 80% methanol. Several com-
pounds were investigated to ﬁnd a suitable internal standard,
and ﬁnally Rasagiline-13C3 mesylate was found to be the most
appropriate internal standard for the present purpose. There
was no signiﬁcant effect of IS on analyte recovery, sensitivity or
ion suppression. High recovery and selectivity was observed in
the liquid–liquid extraction method. These optimized detection
parameters, chromatographic conditions and extraction proce-
dure resulted in reduced analysis time with accurate and precise
detection of Rasagiline in human plasma.
3.2. Method validation
A thorough and complete method validation of Rasagiline in
human plasma was done following US FDA guidelines [10].
The method was validated for selectivity, sensitivity, matrix
effect, linearity, precision and accuracy, recovery, reinjection
reproducibility and stability.
3.2.1. Selectivity and sensitivity
Representative chromatograms obtained from blank
plasma and plasma spiked with a lower limit of quantiﬁcation
(LOQ) sample are shown in Figs. 3 and 4 for Rasagiline and
Rasagiline-13C3 mesylate. The mean % interference observedFigure 3 Blank plasma chromatograms of Rasagilinat the retention time of analytes between six different lots of
human plasma, including hemolyzed and lipedemic plasma
containing K2EDTA as an anti-coagulant was 0.00% and
0.00% for Rasagiline and Rasagiline-13C3 mesylate respec-
tively, which was within acceptance criteria. Six replicates of
extracted samples at the LLOQ level in one of the plasma
sample having least interference at the retention time of
Rasagiline were prepared and analyzed. The % CV of the
area ratios of these six replicates of samples was 1.1% for
Rasagiline, conﬁrming that interference does not affect the
quantiﬁcation at the LLOQ level. The LLOQ for Rasagiline
was 5 pg/mL. All the values obtained below 5 pg/mL for
Rasagiline were excluded from statistical analysis as they were
below the LLOQ values validated for Rasagiline.
3.2.2. Matrix effect
The % CV of ion suppression/enhancement in the signal was
found to be 1.0% at MQC level for Rasagiline, indicating that
the matrix effect on the ionization of analyte is within the
acceptable range under these conditions.
3.2.3. Linearity
The peak area ratios of calibration standards were propor-
tional to the concentration of Rasagiline in each assay over the
nominal concentration range of 5–12000 pg/mL. The calibra-
tion curves appeared linear and were well described by least-
squares linear regression lines. As compared to the 1/xe and Rasagiline-13C3 mesylate in human plasma.
Figure 4 LLOQ chromatograms of Rasagiline and Rasagiline-13C3 mesylate in human plasma.
Table 1 Calibration curve details.
Concentration
(pg/mL)
Mean
(pg/mL)
SD CV
(%)
Accuracy
5.0 4.8 0.0 0.4 96.0
10.0 9.8 0.2 1.7 98.0
100.0 100.5 2.6 2.6 100.5
600.0 595.2 16.7 2.8 99.2
1200.0 1180.6 22.4 1.9 98.4
2400.0 2496.1 69.9 2.8 104.0
4800.0 4505.4 108.1 2.4 93.9
7200.0 7268.4 247.1 3.4 101.0
9600.0 9468.2 236.7 2.5 98.6
12000.0 11864.5 178.0 1.5 98.9
SD: Standard deviation.
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result and was chosen to achieve homogeneity of variance. The
correlation coefﬁcient was Z0.9991 for Rasagiline. The
observed mean back-calculated concentration with accuracy
and precision (% CV) of ﬁve linearity’s analyzed during
method validation is given in Table 1. The deviations of the
back calculated values from the nominal standard concentra-
tions were less than 15%. This validated linearity range
justiﬁes the concentration observed during real sample
analysis.
3.2.4. Precision and accuracy
The inter-run precision and accuracy were determined by
pooling all individual assay results of replicate (n¼6) quality
control over ﬁve separate batch runs analyzed on four
different days. The inter-run, intra-run precision (% CV)
was r5% and inter-run, intra-run accuracy was in between
85 and 115 for Rasagiline. All these data presented in Table 2
indicate that the method is precise and accurate.3.2.5. Recovery
Six aqueous replicates (samples spiked in reconstitution solu-
tion) at low, medium and high quality control concentration
levels for Rasagiline were prepared for recovery determina-
tion, and the areas obtained were compared with the areas
obtained for extracted samples of the same concentration
levels from a precision and accuracy batch run on the same
day. The mean recovery for Rasagiline was 96.9% with a
precision of 2.4%, and the mean recovery for Rasagiline-13C3
mesylate was 96.7% with a precision of 2.1%. This indicates
that the extraction efﬁciency for Rasagiline as well as Rasa-
giline-13C3 mesylate was consistent and reproducible.
3.2.6. Reinjection reproducibility
Reinjection reproducibility exercise was performed to check
whether the instrument performance remains unchanged after
hardware deactivation due to any instrument failure during
real subject sample analysis. The change was less than 2.5% at
LQC and HQC concentration levels; hence batch can be
reinjected in the case of instrument failure during real subject
sample analysis. Furthermore, samples were prepared to be
reinjected after 27 h, which shows % change less than 2.8% at
LQC and HQC concentration levels; hence batch can be
reinjected after 27 h in the case of instrument failure during
real subject sample analysis.
3.2.7. Stabilities
Stock solution stability was performed to check stability of
Rasagiline and Rasagiline-13C3 in stock solutions prepared in
methanol and stored at 2–8 1C in a refrigerator. The freshly
prepared stock solutions were compared with stock solutions
prepared before 28 days. The % change for Rasagiline and
Rasagiline-13C3 mesylate was 0.01% and 0.02% respectively,
which indicates that stock solutions were stable at least for 28
days. Bench top and autosampler stability for Rasagiline was
investigated at LQC and HQC levels. The results revealed that
Table 2 Within-run and between-run precision and accuracy.
Nominal added
concentration
(pg/mL)
Within-run (n¼6) Between-run (n¼36)
Mean
(pg/mL)
SD Precision
(CV, %)
Accuracy Mean
(pg/mL)
SD Precision
(CV, %)
Accuracy
5.0 4.9 0.1 1.3 98.0 5.1 0.1 1.6 102.0
15.0 15.2 0.2 1.3 101.3 15.2 0.2 1.6 101.3
4500.0 4485.6 130.1 2.9 99.7 4465.2 98.2 2.2 99.2
9000.0 8965.3 215.2 2.4 99.6 8965.2 251.0 2.8 99.6
SD: Standard deviation, CV¼Coefﬁcient of variation.
Table 3 Stability of the samples.
Stability experiments Spiked plasma concentration
(n¼6, pg/mL, mean7SD)
Concentration measured
(n¼6, pg/mL, mean7SD)
CV
(%, n¼6)
Room temperature stability (24 h) 15.0 14.970.2 1.3
9000.0 8799.37211.2 2.4
Autosampler stability (55 h) 15.0 15.270.2 1.3
9000.0 8896.47213.5 2.4
Long-term stability (78 days) 15.0 14.670.2 1.3
9000.0 8897.57213.5 2.4
Freeze–thaw stability (cycle 3, 48 h) 15.0 14.970.2 1.3
9000.0 8897.57213.5 2.4
Table 4 Mean pharmacokinetic parameters of Rasagiline
in 22 healthy volunteers after oral administration of 1 mg
(1 1 mg) test and reference products.
Pharmacokinetic parameter Rasagiline
Test Reference
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temperature, and 55 h in an auto sampler at 20 1C. It was
conﬁrmed that repeated freezing and thawing (three cycles) of
plasma samples spiked with Rasagiline at LQC and HQC levels
did not affect their stability. The long-term stability results also
indicated that Rasagiline was stable in a matrix up to 78 days at
a storage temperature of 30 1C. The results obtained from all
these stability studies are tabulated in Table 3.AUC0–t (pg h/mL) 4005.11 4407.78
Cmax (pg/mL) 4529.87 5647.15
AUC0–N (pg h/mL) 4022.33 4434.56
Kel 0.64892 0.59415
t1/2 1.07 1.17
tmax(h) 0.417 0.417
AUC0–N: area under the curve extrapolated to inﬁnity; AUC0–t:
area under the curve up to the last sampling time; Cmax: the
maximum plasma concentration; tmax: the time to reach peak
concentration; Kel: the apparent elimination rate constant. t1/2:
0.693/Kel3.3. Application
The validated method has been successfully used to quantify
Rasagiline concentrations in 22 human volunteers, under fasting
conditions after administration of 1 mg (1 1 mg) tablet con-
taining Rasagiline as an oral dose. The study was carried out
after obtaining signed consent from the volunteers. These
volunteers were contracted in APL Research Centre, Hyderabad,
India. The study protocol was approved from an IEC (indepen-
dent ethics committee) as per DCGI (Drug Control General of
India) guidelines. The pharmacokinetic parameters evaluated
were Cmax (maximum observed drug concentration during the
study), AUC0–6.5 (area under the plasma concentration–time
curve measured 6.5 h, using the trapezoidal rule), tmax (time to
observe maximum drug concentration), Kel (apparent ﬁrst order
terminal rate constant calculated from a semi-log plot of the
plasma concentration versus time curve, using the method of the
least square regression) and t1/2 (terminal half-life as determined
by the quotient 0.693/Kel, Table 4).
The Test/Reference ratios for Cmax, AUC0–6.5, and AUC0–
N were 80.22, 90.86 and 90.70 respectively, and they were
within the acceptance range of 80%–125% demonstrating the
bioequivalence of the two formulations of Rasagiline [11–12].
The mean concentration versus time proﬁle of Rasagiline inhuman plasma from 22 subjects that are receiving 1 1 mg
oral dose of Rasagiline tablet as test and reference is shown in
Figure 5.4. Conclusion
The proposed bio-analytical method is simple, highly sensitive,
selective, rugged and reproducible. The major advantage of
this method is rapid analysis time (3 min), less plasma volume
(0.1 mL) usage for analysis, suitable internal standard usage.
This method was successfully applied in bioequivalence study
to evaluate the plasma concentrations of Rasagiline in healthy
human volunteers.
Figure 5 Mean plasma concentrations of test versus reference
after 1 mg dose (1 1 mg tablet) in 22 healthy volunteers.
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